The United States Food and Drug Administration has ordered a class-wide label change for GLP-1 drugs, putting the GLP-1 eye stroke risk warning on every product in the group. The agency said on Monday 9 November that makers of all glucagon-like peptide-1 receptor agonists must add a warning about non-arteritic anterior ischemic optic neuropathy, known as NAION, to the Warnings and Precautions section of their labels. The condition is sometimes called an eye stroke because it cuts blood flow to the optic nerve and can cause sudden, painless vision loss in one eye.
The warning lands as use of the drugs climbs fast in India. PharmaTrac data put the Indian GLP-1 market at Rs 2,333 crore in the 12 months to August 2026, up from Rs 153 crore in August 2022. Eli Lilly’s Mounjaro, launched in India in March 2025, is now the country’s top-selling drug by value, with sales of Rs 1,256 crore in the same 12 months, up 502 per cent. Generic semaglutide arrived in March 2026, and monthly sales rose from about 20,000 units to about 60,000 units. The GLP-1 eye stroke risk warning therefore reaches a market far bigger than a year ago.
The decision rests on clinical trials, real-world records and adverse event reports. In an analysis of 126 randomised controlled trials covering 134,253 patients, the agency found 15 probable NAION cases: 6.4 cases per 100,000 person-years among GLP-1 users against 3.8 in the comparison groups. The GLP-1 eye stroke risk figures show the risk is rare in absolute terms, and the FDA calls it a potential increased risk, not proof that the drugs cause the condition. Its review of animal data found no mechanism by which the drugs would raise the risk.
GLP-1 eye stroke risk in the trial data
Observational studies gave a mixed picture. In the FDA’s real-world study of adults with type 2 diabetes, the risk was 43 per cent higher than with DPP-4 inhibitors, a hazard ratio of 1.43, but there was no statistically significant increase against SGLT2 inhibitors. Two Scandinavian studies of semaglutide found a higher risk, and a United States health records study put the risk 76 per cent higher than with other diabetes drugs. A Cleveland Clinic study of about 220,000 GLP-1 users found no statistically significant increase. The European Medicines Agency has said semaglutide carries about a two-fold increase in risk and classed NAION as a very rare side effect.
NAION happens when blood flow to the front of the optic nerve drops suddenly. The vision loss usually affects one eye and is noticed on waking, and no proven treatment restores sight once it has occurred. People with a crowded optic disc carry a higher risk, as do people with diabetes, high blood pressure, sleep apnoea, smoking and kidney disease. The GLP-1 eye stroke risk warning tells doctors to ask patients to report sudden vision changes at once and to send suspected cases to an ophthalmologist the same day.
What the GLP-1 eye stroke risk warning means for patients
The GLP-1 eye stroke risk label change covers all 12 GLP-1 products on the FDA list, from Ozempic, Wegovy, Mounjaro and Zepbound to the new oral drug orforglipron, sold as Foundayo. It is a change to the Warnings and Precautions section, not a boxed warning, and it is not a recall or a ban. Eli Lilly has said it is carefully evaluating the update and will respond to the FDA promptly. As of 1 October, 247 cases were pending in federal litigation over NAION in the United States.
The GLP-1 eye stroke risk warning says that if NAION develops, doctors should consider stopping the drug unless the benefits clearly outweigh the risk. The American Optometric Association has recommended a baseline eye exam to check optic nerve health for new GLP-1 users since 2025. The advice covers people who take the drugs for weight loss as well as for diabetes. The FDA has not given a deadline for the new labels to appear.
In India the drugs are used for type 2 diabetes and for weight loss, and an ICMR-INDIAB study has estimated that 254 million people in India live with obesity and 101 million with diabetes. In January 2026 the Indian regulator’s subject expert committee recommended permission for manufacture and marketing of synthetic semaglutide injections from MSN Laboratories, subject to post-marketing safety reporting. The GLP-1 eye stroke risk warning adds a new safety question as use of the drugs keeps growing.